ReviewPathogens (Basel, Switzerland)2020
Human T-cell Leukemia Virus Type 1 and
Review in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human T-Cell Lymphotropic Virus Type 1 andFrontiers in medicine · 2022Pooled it
- Article
- Routine Screening of Strongyloides Among Patients With Lymphoma and Efficacy of Targeted Prophylaxis.American journal of hematology · 2025Article
- Epidemiological, clinical and immunological features of Schistosoma spp., Stronglyoides stercoralis and Taenia spp. infections in Ghanaian HIV patients.European journal of microbiology & immunology · 2025Article
- Discovery of Galangin Derivatives as a Potential T-cell Leukemia Virus 1 Protease Inhibitor Through Chemoinformatics Approaches.Cell biochemistry and biophysics · 2025Article
- Succinic semialdehyde derived from the gut microbiota can promote the proliferation of adult T-cell leukemia/lymphoma cells.Heliyon · 2024Article
- Case Report: Disseminated Paracoccidioidomycosis and Strongyloides Hyperinfection in a Patient with Human T-Lymphotropic Virus Type 1/2 Infection.The American journal of tropical medicine and hygiene · 2024Article
- Human strongyloidiasis: complexities and pathways forward.Clinical microbiology reviews · 2023Review
- New Perspectives about Drug Candidates Targeting HTLV-1 and Related Diseases.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review.Biomolecules · 2023Review
- Article
- Cancerogenic parasites in veterinary medicine: a narrative literature review.Infectious agents and cancer · 2023Review
- Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review.The American journal of tropical medicine and hygiene · 2023Article
- Seroprevalence ofTropical medicine and infectious disease · 2023Article
- A case ofIDCases · 2023Article
- Strongyloides stercoralis.Lung · 2022Review
- A case ofIDCases · 2022Article
- Mechanisms Involved in the Promoting Activity of Fibroblasts in HTLV-1-Mediated Lymphomagenesis: Insights into the Plasticity of Lymphomatous Cells.International journal of molecular sciences · 2021Article
- HTLV-1 Disease.Pathogens (Basel, Switzerland) · 2021Article
- Strongyloides stercoralis and HTLV-1 coinfection in CD34+ cord blood stem cell humanized mice: Alteration of cytokine responses and enhancement of larval growth.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Infection with human T-cell leukemia/lymphoma virus type 1 (HTLV-1) has been associated with various clinical syndromes including co-infection with
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.